Tag: FDA Section 505A

Pediatric Exclusivity: How the FDA Extends Market Protection for Drugs

By Joe Barnett    On 28 Nov, 2025    Comments (14)

blog-post-image

Pediatric exclusivity gives drugmakers six extra months of market protection after completing FDA-requested studies in children. It doesn't extend patents but blocks generic approval, even after patent expiration, ensuring safer pediatric dosing.

View More

Categories

Recent Post

recent-post-image Understanding Risk-Benefit Statements in FDA Drug Labels: What Patients Need to Know
recent-post-image Geriforte Syrup vs Alternative Cough Syrups - Full Comparison Guide
recent-post-image Direct-to-Consumer Generic Pharmacies: How New Business Models Are Changing How You Get Medications
recent-post-image Severe Adverse Drug Reactions: When to Seek Emergency Help
recent-post-image Intra-Articular Steroid Injections: What You Need to Know About Systemic Side Effects and Limits

Menu

© 2026. All rights reserved.